Toll Free: 1-888-928-9744

Circadian Technologies Limited - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Circadian Technologies Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Circadian Technologies Limited - Product Pipeline Review - 2014', provides an overview of the Circadian Technologies Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Circadian Technologies Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Circadian Technologies Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Circadian Technologies Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Circadian Technologies Limited's pipeline products

Reasons to buy

- Evaluate Circadian Technologies Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Circadian Technologies Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Circadian Technologies Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Circadian Technologies Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Circadian Technologies Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Circadian Technologies Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Circadian Technologies Limited Snapshot 4
Circadian Technologies Limited Overview 4
Key Information 4
Key Facts 4
Circadian Technologies Limited - Research and Development Overview 5
Key Therapeutic Areas 5
Circadian Technologies Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
Circadian Technologies Limited - Pipeline Products Glance 11
Circadian Technologies Limited - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Circadian Technologies Limited - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Circadian Technologies Limited - Drug Profiles 13
VGX-100 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
OPT-302 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
VGX-200 Series 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Circadian Technologies Limited - Pipeline Analysis 17
Circadian Technologies Limited - Pipeline Products by Target 17
Circadian Technologies Limited - Pipeline Products by Route of Administration 18
Circadian Technologies Limited - Pipeline Products by Molecule Type 19
Circadian Technologies Limited - Pipeline Products by Mechanism of Action 20
Circadian Technologies Limited - Recent Pipeline Updates 21
Circadian Technologies Limited - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27
List of Tables
Circadian Technologies Limited, Key Information 4
Circadian Technologies Limited, Key Facts 4
Circadian Technologies Limited - Pipeline by Indication, 2014 6
Circadian Technologies Limited - Pipeline by Stage of Development, 2014 7
Circadian Technologies Limited - Monotherapy Products in Pipeline, 2014 8
Circadian Technologies Limited - Out-Licensed Products in Pipeline, 2014 9
Circadian Technologies Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 10
Circadian Technologies Limited - Phase I, 2014 11
Circadian Technologies Limited - Preclinical, 2014 12
Circadian Technologies Limited - Pipeline by Target, 2014 17
Circadian Technologies Limited - Pipeline by Route of Administration, 2014 18
Circadian Technologies Limited - Pipeline by Molecule Type, 2014 19
Circadian Technologies Limited - Pipeline Products by Mechanism of Action, 2014 20
Circadian Technologies Limited - Recent Pipeline Updates, 2014 21
Circadian Technologies Limited, Subsidiaries 25 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify